With a market cap of $155.2 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. Based in Marlborough, Massachusetts, the company operates in two segments, MedSurg and Cardiovascular.

Shares of BSX have considerably surpassed the broader market over the past year. BSX has gained 45.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 12.3%. In 2025, BSX gained 17.5%, compared to $SPX’s 3.3% decline.

Narrowing the focus, BSX has also outperformed the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has surged 9.6% over the past year and 3.6% this year.

Boston Scientific closed up more than 4% on Apr. 22 after releasing its Q1 earnings. It boosted its full-year net sales forecast to 15% to 17% from a prior view of 12.5% to 14.5%. Additionally, the company’s EPS came in at $0.75, surpassing the Street’s forecast by 11.9%.

For the current year, ending in December, analysts expect BSX’s EPS to increase 15.9% year over year to $2.91. The company’s earnings surprise history is impressive. It surpassed the consensus estimate in each of the last four quarters.

BSX’s stock has a consensus “Strong Buy” rating. Out of 28 analysts covering the stock, 25 rate it as a "Strong Buy," two suggest a "Moderate Buy," and one say "Hold."

This configuration remained unchanged for the past three months.

On Apr. 25, Barclays plc (BCS) analyst Matt Miksic raised the firm’s price target on Boston Scientific to $125 from $118 and keeps an “Overweight” rating on the shares. The firm said ADVANTAGE-AF’s solid results for the use of Farawave and Farapoint in persistent atrial fibrillation should support FDA approval later this year.

The mean price target of $120.03 suggests a 14.4% premium to BSX’s current price levels. Moreover, the Street-high target of $135 suggests an impressive upside potential of 28.7%.